Centogene

What Centogene does

Centogene GmbH is a Rostock-headquartered, multiomic genetic diagnostics company founded in 2006, publicly held through Centogene N.V. (Nasdaq:CNTG, now OTC:CNTGF) and operating under the ownership of Charme Capital Partners following the November 2024 sale of operating subsidiaries for EUR 8.7M. The company provides clinical genetic and multiomic testing—Whole Genome Sequencing (CentoGenome and CentoGenome Ultra-Fast), Whole Exome Sequencing (CentoXome), chromosomal microarray analysis (CentoArray), NIPT (CentoNIPT), carrier screening (CentoScreen), and customizable panels—anchored by its proprietary CentoCard dried blood spot sample collection platform and its >1M-patient Biodatabank spanning 120+ countries with over 70% non-European descent. Its MOx platform integrates genomic, transcriptomic, proteomic, and metabolomic data from a single sample, supported by an AI-assisted variant interpretation stack (CentoDx) and a free lifelong variant reclassification program.

The company operates three revenue streams. Clinical genetic testing services are billed per test to physicians, healthcare providers, and patients across approximately 30,000 active physicians and regional customer support hubs in APAC, Brazil, Canada, LATAM, Mexico, Spain & Portugal, UAE, and the US, with self-serve ordering through CentoPortal and specialized IVF ordering portals. Pharmaceutical partnerships generate revenue through clinical trial support, patient identification and stratification, sponsored testing programs (e.g., EFRONT, TRAMmoniTTR, ROPAD), and biodatabank access, with Agios disclosed as a named partner. Reproductive health services include PGT-A, CentoNIPT, and carrier screening for IVF clinics.

Centogene holds a dense regulatory stack—ISO 13485, CAP ISO 15189, CLIA (Rostock and Miami labs), ISO/IEC 27001, PCI DSS, and EU IVDR compliance—and reports over 350 peer-reviewed publications and 19,000+ genes in its testing portfolio. Following its Nasdaq delisting and PE-backed restructuring, the company is pursuing geographic expansion (Saudi Arabia JV with Lifera, Brazil acquisition) and product expansion (PGT-A, CentoPediatric, CentoScreen Exome), while historically operating at a revenue level around USD 50M with persistent operating losses.

Name

Centogene

Legal name

CENTOGENE GmbH

Website

https://centogene.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Centogene is a Rostock-based, PE-owned multiomic genetic diagnostics company that serves approximately 30,000 physicians and pharmaceutical partners with whole genome, exome, and reproductive health testing powered by its CentoCard platform and >1M-patient Biodatabank spanning 120+ countries.

Ownership category

akta.pro rank

Product category

Clinical Genetic Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Genetic diagnostics services
• Multiomic testing
• Rare disease screening
• Reproductive genetics
• Clinical genomic sequencing

Headquarters

HQ city

Rostock

HQ country

Germany

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Genetic Testing Services: Comprehensive genetic and multiomic testing services for physicians and patients including Whole Genome Sequencing (CentoGenome), Whole Exome Sequencing (CentoXome), NGS Panels, CentoArray, and specialized tests. Revenue generated through test fees billed to healthcare providers, insurance, and patients.
2. Pharma Partnerships and Research Services: Partnering with pharmaceutical companies to accelerate drug discovery and development through patient identification and stratification, clinical trial support, and access to the biodatabank. Includes sponsored testing programs and registry studies (EFRONT, TRAMmoniTTR, ROPAD).
3. Reproductive Health Services: Genetic testing services for reproductive health including PGT-A (Preimplantation Genetic Testing for Aneuploidy), carrier screening, CentoNIPT (Non-invasive prenatal testing), serving IVF clinics and reproductive genetics providers.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

CENTOGENE provides clinical genetic and multiomic diagnostic testing services, including whole genome sequencing (CentoGenome), whole exome sequencing (CentoXome), chromosomal microarray analysis (CentoArray), non-invasive prenatal testing (CentoNIPT), carrier screening, and preimplantation genetic testing (PGT-A), supported by its proprietary CENTOGENE Biodatabank of over 1 million patients and CentoCard dried blood spot sample collection technology. The company serves physicians, healthcare providers, pharmaceutical partners, and IVF clinics globally with rare and neurodegenerative disease diagnostics.

Product overview

CENTOGENE offers a comprehensive genetic and multiomic diagnostic portfolio centered around whole genome sequencing (CentoGenome), whole exome sequencing (CentoXome), and chromosomal microarray analysis (CentoArray). The portfolio includes specialized solutions such as CentoNIPT for prenatal testing, CentoScreen for carrier screening, and CentoCustom Panel for customizable testing. The MOx (Multiomic Solutions) platform integrates genomic, biochemical, and transcriptomic data combining WGS/WES with RNA sequencing and enzyme/metabolite analysis. Supporting infrastructure includes CentoCard for sample collection, CentoPortal for online ordering and report management, and CentoDx/CentoCloud for bioinformatics and variant interpretation. The company serves clinical diagnostics, pharmaceutical partners through registries and sponsored testing programs, and reproductive genetics markets.

Differentiator

Problem solved

Functional benefit

Brands

• CentoGenome: Whole Genome Sequencing solution - one of the world's most comprehensive tools for diagnosing rare and neurodegenerative diseases
• CentoXome
• CentoArray
• CentoCard
• CentoPortal
• CentoNIPT
• CentoMD
• CentoDx
• MOx
• CentoScreen

Products and services

• CentoGenome Whole Genome Sequencing (WGS) solution providing comprehensive genome coverage and diagnostic power for rare and neurodegenerative diseases, detecting nearly all variant types including SNVs, CNVs, repeat expansions, and mitochondrial variants.
• CentoGenome Ultra-Fast Rapid whole genome sequencing variant with results delivered in just 5 business days, designed for critically ill patients in ICU, neonatal, and emergency settings where rapid genetic diagnosis is crucial.
• CentoXome

Quantifiable outcome

• Diagnostic yield improvement through multiomic approach enabling integration of DNA, RNA, and biochemical data
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• BianalisicoreChannel Partner/ Reseller/ Distributor · 27 May 2025Strategic partnership announced at ESHG2025 in Milan, Italy. Bianalisi is an Italian diagnostic company serving as a channel partner for expanded distribution and market access in the Italian market.
• Critical Path Institute (C-Path)coreStrategic or Co-development Partner · 20 June 2024Memorandum of Understanding to enhance collaboration in lysosomal disease research and drug development. Aims to leverage combined expertise and data resources to accelerate therapeutic development for lysosomal storage diseases.
• LiferacoreStrategic or Co-development Partner · 28 June 2023Joint venture in Saudi Arabia with Lifera, a biopharmaceutical company owned by Saudi Arabia's Public Investment Fund. Aims to establish advanced genetic testing and bioinformatics facilities to enhance Saudi Arabia's biopharmaceutical sector. CENTOGENE contributes expertise and receives $30 million convertible loan, performance milestones, and royalties until 2033. Formation expected in late 2023.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• GeneDx (formerly Sema4): Specialist in rare disease and pediatric clinical genomics with a focus on whole exome/genome sequencing. Closest US-based direct competitor to Centogene's rare-disease and pediatric diagnostic franchise.
• NeoGenomics: Specialty oncology and rare disease clinical laboratory with both clinical and pharma services. Comparable business mix combining clinical diagnostics with pharma/biotech trial support.
• Invitae: Clinical genetic testing company offering comprehensive hereditary disease panels, exome, and genome sequencing. Directly comparable to Centogene in clinical genetic diagnostics, although Invitae has stronger US payer reach and underwent a 2024 restructuring that mirrors Centogene's challenges.
• Natera: Reproductive health (NIPT, PGT) and oncology genetic testing company. Direct overlap with Centogene's reproductive health segment (CentoNIPT, PGT-A, CentoScreen) and similar business model of high-volume specialty diagnostics.
• Ambry Genetics: Clinical genetics laboratory offering exome, genome, and panel testing across hereditary disease areas. Comparable in clinical genomic testing focus, particularly in rare disease and hereditary cancer.
• PreventionGenetics (part of Exact Sciences): Clinical genetic testing laboratory specializing in hereditary disease, reproductive, and whole genome/exome testing. Acquired by Exact Sciences in 2022, comparable in clinical rare-disease diagnostics scope and customer base.
• Myriad Genetics: Molecular diagnostics company with hereditary cancer, pharmacogenomic, and prenatal testing portfolios. Comparable in scale and clinical genomics business model, with strong pharma partnership capability.

Broad incumbents

• Quest Diagnostics: Major US clinical reference laboratory with growing specialty genetics and reproductive health offerings. Broad incumbent providing scaled alternative to Centogene for hospital systems and physician networks.
• Labcorp: Large diversified clinical reference laboratory offering broad specialty genetic and molecular diagnostic services. Overlaps with Centogene in clinical genomics but operates at substantially greater scale and breadth.
• Eurofins Scientific: European-headquartered clinical diagnostics and bioanalytical testing conglomerate. Provides comparable European footprint and specialty clinical lab services including reproductive genetics and rare disease testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/Centogene
• YouTubeyoutube.com/channel/UClZxtN_laC1_ZtCdxkasdPQ
• Facebookfacebook.com/centogene
• LinkedInlinkedin.com/company/centogene-ag
• Instagraminstagram.com/centogene_ag

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centogene